Epigenomics increases share capitalal
30-Oct-2013
- Germany
Following completion of the placement, the Supervisory and Executive Boards of the Company are going to resolve on the final amount of shares to be issued.
Epigenomics AG intends to use the net proceeds from the offering to finance its current operations and to build and strengthen the distribution capacities for its lead product Epi proColon®, a blood-based test for the detection of colorectal cancer.
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.